GM Mosquito Cuts Wild-Type Numbers

Release of a transgenic version of Aedes aegypti, a species that can carry dengue virus, decimated a local population of non-mutated mosquitoes, according to a study.

Written byKerry Grens
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

FREESTOCKPHOTOS.BIZ, CDC/PROF FRANK HADLEY COLLINSA genetically modified (GM) mosquito—designed to infiltrate a wild population and produce offspring that die before reproductive age—has devastated local mosquito numbers in a field trial in Brazil. Researchers reported in PLOS Neglected Tropical Diseases this month (July 2) that one year after deployment of the mutant Aedes aegypti, mosquito numbers were reduced 80 percent to 95 percent.

“The fact that the number of Aedes aegypti adults were reduced by 95% in the treatment area confirms that the Oxitec mosquito does what it is supposed to and that is to get rid of mosquitoes,” study coauthor Andrew McKemey, head of field operations at Oxitec, which developed the GM mosquito, said in a press release.

Aedes aegypti can carry pathogens that cause diseases, including dengue and chikungunya. Although McKemey’s study did not determine whether disease burden among humans would drop with the introduction of GM mosquitoes, he said in the statement that “according to published mathematical models reviewed and recommended by the World Health Organization (WHO) working group on dengue, it would . . . reduce the number of biting mosquitoes below the disease ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • kerry grens

    Kerry served as The Scientist’s news director until 2021. Before joining The Scientist in 2013, she was a stringer for Reuters Health, the senior health and science reporter at WHYY in Philadelphia, and the health and science reporter at New Hampshire Public Radio. Kerry got her start in journalism as a AAAS Mass Media fellow at KUNC in Colorado. She has a master’s in biological sciences from Stanford University and a biology degree from Loyola University Chicago.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies